ST-segment elevation myocardial infarction in a patient with thrombophilia taking new oral anticoagulants;Infarto miocardico acuto in corso di terapia con nuovo anticoagulante orale in paziente con trombofilia

Giornale Italiano di Cardiologia

Volumn 17, Issue 6, 2016, Pages 23S-25S

  Calzi, Mauro Li ^a   Placci, Angelo ^a   Lina, Daniela ^a   Grassi, Francesca ^a   Paoli, Giorgia ^a   Bianconcini, Michele ^a   Cattabiani, Maria Alberta ^a   Menozzi, Alberto ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; RIVAROXABAN; THROMBOPLASTIN; WARFARIN; ANTICOAGULANT AGENT;

ACUTE CORONARY SYNDROME; AGED; ANGIOGRAPHY; ARTICLE; CASE REPORT; COMPLETE HEART BLOCK; CORONARY ARTERY THROMBOSIS; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY TREATMENT; FEMALE; GENE; GENE MUTATION; HETEROZYGOSITY; HUMAN; LABORATORY TEST; LOW DRUG DOSE; LUNG EMBOLISM; RECURRENT IDIOPATHIC PULMONARY EMBOLISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; THROMBOPHILIA; COMPLICATION; HEART INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; FEMALE; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RIVAROXABAN; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 84984706990     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: 10.1714/2292.24644     Document Type: Article

References (11)

1. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-69.
2. Buller HR, Prins MH, Lensin AW, et al.; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
3. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
4. Schaefer JK, McBane RD, Black DF, Williams NL, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients. Thromb Haemost 2014;112:947- 50.
5. Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2011;89:1017.
6. Son M, Wypasek E, Lowenhoff-Celinska M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. Thromb Res 2015;135:1035-6.
7. Cavender MA, Gibson CM, Braunwald E, et al. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care 2015;4:468-74.
8. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
9. Hess CN, James S, Lopes RD, et al. Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial. J Am Coll Cardiol 2015;66:777-87.
10. Oldgren J, Budaj A, Granger CB, et al.; RE-DEEM Investigators. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9.
11. Povsic TJ, Roe MT, Ohman EM, et al. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. Am Heart J 2016;174:120-8.